When exogenous testosterone therapy is. adverse responses can be induced.
|
|
- Harry Barrett
- 6 years ago
- Views:
Transcription
1
2 Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release of testosterone and possible stimulation of remaining androgen sensitive elements. When exogenous testosterone therapy is administeredto to patients with symptomatic CRPC, adverse responses can be induced.
3
4 Taylor (JCO 1993) retrospective (341 pts) continued testicular androgen suppression was an important tpredictor of survival lduration (modest advantage) Hussain (JCO 1994) retrospective (205 pts) no obvious bi advantages in response to chemotherapy or survival for pts with continued gonadal suppression Lee (Am J Clin Oncol 2011) prospective (78 pts) brr (48.7% vs 66.7% p=0.27) PFS (4.9 mosvs5.0 mos p=0.57)
5 ADT is advocated to be used continuously, when chemotherapy is proposed p for CRPC
6 No robust evidences support the ADT maintenance during chemo Theoretical advantages could be postulated If well tolerated, ADT may be continued
7
8 1990 s scenario HT XRT PIB HT HT CHT RP HT CHT hormone res metastases
9 Mitoxantrone Tannock JCO 1996; 14:1756 MIT+PDN PDN Kantoff JCO 1999; 17: 2506 MIT+HC HC Better palliation with MIT Increased DFS with MIT No differences in survival
10 SWOG and TAX studies in HRPC
11 TAX327 original results Pr robability of Surviving D 3 wkly 0.8 D wkly 0.7 Mitoxantrone Median Hazard Survival Ratio P value Combined: D 3 wkly: D wkly: Mitoxantrone: Months Tannock et al, N Engl J Med 2004; 351: months
12 TAX327 confirmatory data of survivi ing Pro obability Docetaxel q3w Docetaxel qw Mitoxantrone Median survival Hazard (months) ratio p value Docetaxel q3w: Docetaxel qw: Mitoxantrone Years months 48 months Berthold DR, et al. J Clin Oncol 2008;26:
13 1990 s scenario HT XRT PIB HT HT CHT RP HT CHT hormone res metastases
14 2004 scenario HT XRT PIB HT HT CHT RP HT CHT hormone res metastases
15
16 M0 Maintain castration levels of testosterone Clinical trial Observation Further hormonal manipulation ASYMPTOMATIC M1 Maintain castration levels of testosterone SYMPTOMATIC only bone mets DOC Zoledronic acid SYMPTOMATIC visceral mets DOC
17 TAX327:Multivariate Cox proportional p hazards Variable Multivariate 95% CI p value HR Liver metastases Number of metastatic sites (>2 vs 2) Pain at baseline < Performance status ( 70 vs 80) Progression type Measurable disease Bone scan Baseline PSA doubling time (<55 days vs 55 days) Baseline log PSA (for every unit rise in log(psa) in ng/dl) <0.001 Tumour grade (Gleason 8 or WHO 3 4 vs Gleason 7 or WHO 2 3) Alkaline phosphatase (log scale) (per log unit rise, IU/L Haemoglobin) Haemoglobin (per unit rise, g/dl) Armstrong et al Clin Canc Res 2007;13:
18 Prognostic Nomogram in CRPC Chemotherapy type Liver metastases Number of sites Pain at baseline Points Weekly Doce (6) Q3 Doce Mitox (18) No Yes (23) <=2 >2 (22) No Yes (18) Karnofsky performance status >=80 <70 (15) Progression type: Measurable disease No Yes (15) Progression type: Bone scan progression No Yes (12) Tumour grade Baseline PSA (ng/ml) Alkaline phosphatase (IU/L) Haemoglobin (g/dl) Baseline PSA doubling time Total points Median survival time (mo) Low Grade 0 18 High Grade (8) (5) 1 2 (13) 14 >6 2 3 (12) <1 (19) yr survival probability yr survival probability 5 yr survival probability Armstrong et al Clin Canc Res 2007;13:
19 Simplified Model Risk factors Anemia (hemoglobin <13.0) laboratory data Progression by bone scan criteria clin. data Visceral metastases clin. data Presence of clinically significant pain (TAX 327 definition) clin. data Armstrong et al Clin Canc Res 2007;13:
20 Simplified Model
21 Simplified Model Low Risk: 0-1 risk factors Intermediate Risk: 2 risk factors High Risk: 3-4 risk factors
22
23 TAX 327 Survival: pain vs no pain/minimal Docetaxel q3w Docetaxel qw Mitoxantrone (n = 335) (n = 334) (n = 337) N O P A I N P A I N n Median survival Hazard ratio p value n Median survival Hazard ratio p value Berthold DR, et al. J Clin Oncol 2008;26:242 45
24 TAX 327 Survival: pain vs no pain/minimal Docetaxel q3w Docetaxel qw Mitoxantrone (n = 335) (n = 334) (n = 337) N O P A I N P A I N n Median survival Hazard ratio p value n Median survival Hazard ratio p value Berthold DR, et al. J Clin Oncol 2008;26:242 45
25 Pre Treatment PSA DT PSADT >6 months PSADT 4 6 months PSADT 2 3 months PSADT 1 2 months PSADT <1 month Surviva al (%) and 3-6 Med OS NYR mean OS 25 and 22.5 months < 1 mo months 0 Log-rank p< Survival (months) Armstrong et al Clin Canc Res 2007;13:
26 Overall Survival according to bone pain intensity i and PSA doubling time (DT) No or minimal pain Mild pain Moderate or severe (n=79) (n=41) pain (n=25) Median OS 21.4 mos ( ) 15 mos ( ) 13.1 mos ( ) PSA DT > 45 days 32.4 mos 18.4 mos 16.1 mos PSA DT < 45 days 16.5 mos 11.2 mos 8.3 mos OS at 1 year (%) 75% 56% 52% OS at 2 years (%) 43% 20% 20% OS at 3 years (%) 29% 11% 4% S. Oudard et al, 2009, 103, 12:
27 M0 Maintain castration levels of testosterone Clinical trial Observation Further hormonal manipulation ASYMPTOMATIC M1 Maintain castration levels of testosterone SYMPTOMATIC only bone mets DOC Zoledronic acid SYMPTOMATIC visceral mets DOC
28 M0 Maintain castration levels of testosterone Clinical trial Observation Further hormonal manipulation ASYMPTOMATIC T slow growth Clinical trial Further hormonal manipulation Immunotherapy M1 Maintain castration levels of testosterone ASYMPTOMATIC fast growth SYMPTOMATIC only bone mets DOC Clinical trial DOC Zoledronic acid SYMPTOMATIC visceral mets DOC
29 Symptomatic CRPC patients should start CT as soon as possible Asymptomatic CRPC patients with aggressive features should start CT before PS worsening Asymptomatic CRPC patients with no aggressive features should be enrolled in clinical trials or should undergo watchful waiting (no advantages from further HTs)
30
31 New HTs CT Abiraterone Enzalutamide Cabazitaxel Cabazitaxel Doc cetaxel CT New HTs Cabazitaxel Cabazitaxel Abiraterone Enzalutamide New HTs New HTs Abiraterone Enzalutamide Enzalutamide Abiraterone 3 strategies t 6 combinations
32 Abiraterone Enzalutamide Enzalutamide Abiraterone Cabazitaxel Enzalutamide Cabazitaxel Abiraterone Cabazitaxel Cabazitaxel Abiraterone Enzalutamide Abiraterone Cabazitaxel Enzalutamide Cabazitaxel Enzalutamide Abiraterone
33 CT HT vs HT CT
34 CT HT vs HT CT Author sequence # pts brr mos Mezynski ABI DOC 35 26% 12.5 m Aggarwal* KETO DOC % 21.1 m Pond** KETO DOC % 17.0 m *no differences compared to 728 pts not treated with KETO ** better trend without significance compared to 180 pts not treated with KETO after adjustment
35 Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel inmetastatic castration resistant resistant prostate cancer (mcrpc). 113 pts assessed 77 pts 36 pts Caba Abi Abi Caba Median OS, TTF1, and TTF2 were analyzed by Kaplan Meier method from start of second line therapy post D to death for OS, to end of second line (TTF1), and to end of combined second and third line therapies (TTF2). Sonpavde et al. ESMO 2013, abs 2905
36 Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel inmetastatic castration resistant resistant prostate cancer (mcrpc). Sonpavde et al. ESMO 2013, abs 2905
37 Outcomes with different sequences of cabazitaxel and abiraterone acetate following docetaxel inmetastatic castration resistant resistant prostate cancer (mcrpc). Median TTF1 Median TTF2 DCA: 5.2 mos (95% CI 4.3 7) DCA: 10.4 mos (95% CI ) DAC: 4.3 mos (95% CI ) DAC: 7.1 mos (95% CI ) Sonpavde et al. ESMO 2013, abs 2905
38 Sella a et al. ASCO GU 2013 Abs 186
39 Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mcrpc) treated with cabazitaxel: Sequencing mightmatter. matter. Angelergues et al. J Clin Oncol 31, 2013 (suppl; abstr 5063)
40 ENZ ABI vs ABI ENZ
41 ENZ ABI vs ABI ENZ
42 ENZ ABI vs ABI ENZ Author sequence # pts brr mpfs Loriot ENZ ABI 38 8% 2.7 m Noonan ENZ ABI 30 3% 3.8 m Schrader ABI ENZ % NR Bianchini ABI ENZ % 28m 2.8
43 A decision making flow chart proposal Gallardo et al. Crit Rev Oncol/Hemat 2013, in press
44 l id i No clear evidence supports one sequencing strategy vs another Preliminary and observational experiences suggest CABA before HTs seems to provide better survival outcomes HT HT activity seems to be limited To date the sequencing strategy should be tailored to the single patient profile (when it is possible, more lines seem better)
45
46 Sipuleucel T: Autologous APCs Cultured with Antigen Fusion Protein Recombinant Prostatic Acid Phosphatase (PAP) fusion antigen combines with resting antigen presenting cell (APC) APC takes up the antigen Antigen is processed and presented on surface of the APC Active T-cell Fully activated, the APC is now sipuleucel-t Inactive INFUSE PATIENT T-cell T-cells proliferate and attack cancer cells sipuleucel-t activates T-cells in the body The precise mechanism of sipuleucel-t in prostate cancer has not been established.
47 PSA TRICOM (PROSTVAC) is a vector based vaccine consisting of recombinant fowlpox boosts which contains transgenes for PSA and three co stimulatory molecules (TRICOM)
48 Randomized Phase 3 IMPACT Trial (IMmunotherapy Prostate AdenoCarcinoma Treatment) Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate t Cancer (N=512) 2:1 Sipuleucel-T Q 2 weeks x 3 Placebo Q 2 weeks x 3 P R O G R E S S I O N Treated at Physician Discretion Treated at Physician Discretion and/or Salvage Protocol S U R V I V A L Primary Endpoint: Overall Survival Secondary Endpoint: Objective Disease Progression
49 P = (Cox model) HR = [95% CI: 0.614, 0.979] Median Survival Benefit = 4.1 Mos. (25.8 vs 21.7)
50 Metastatic Castration Resistant Prostate Cancer (N=125) 2:1 PROSTVAC Q 4 weeks x 6 Placebo Q 4 weeks x 6 Primary Endpoint: Progression Free Survival
51
52
53 Tumor Growth Rate Tumor Bu urden Time
54 Sipuleucel T: Logistics of Therapy Day 1 Day 2-3 Day 3-4 Leukapheresis sipuleucel-t is manufactured Patient is infused Apheresis Center Central Processing Doctor s Office COMPLETE COURSE OF THERAPY: COMPLETE COURSE OF THERAPY: Weeks 0, 2, 4
55 No clear evidences supports the advantages of an immunotherapy strategy for the largest majority of CRPC pts Economic and factory matters will limit its use in Italian context
56
57 parameters clinical issues performance status pain laboratory issues PSA bone biomarkers imaging issues CT scan bone scan PET scan (??)
58 objectives true PD to avoid late therapy stop (for on treatment pts) to avoid later therapy start (for off treatment pts) false PD to avoid early therapy stop (for on treatment pts) to avoid early therapy start (for off treatment pts)
59 on treatment regular PSA assessment biochemical PD requires radiological confirmation of progression to lead to therapy end regular clinical status assessment baseline and final instrumental assessment CT : on demand during the treatment HT : every 4 6 months
60 off treatment regular PSA assessment biochemical PD should be confirmed by radiological assessment clinical status should be regularly monitored to avoid a deterioration which prevents further treatments to detect symptoms appearance no regular instrumental follow up should be planned
When exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationSession VI A: Prostate Cancer Multidisciplinary Approach: a key to success
EORTC-GU Group Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success Joaquim Bellmunt Geriatric Oncology: Cancer in Senior Adults. Madrid Melia Castilla, 8-10 November 2007. Multidisciplinary
More informationUpdated Results of the IMPACT. Metastatic, Castration-Resistant Prostate Cancer (CRPC)
Updated Results of the IMPACT Trial of Sipuleucel-T Tfor Metastatic, Castration-Resistant Prostate Cancer (CRPC) Philip Kantoff, MD Dana-Farber a abe Cancer Institute ue Professor of Medicine Harvard Medical
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationEvolution of Chemotherapy for. Cancer
Evolution of Chemotherapy for Hormone Refractory Prostate t Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology Princess Margaret Hospital and University of Toronto In 1985, two
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationName of Policy: Cellular Immunotherapy for Prostate Cancer
Name of Policy: Cellular Immunotherapy for Prostate Cancer Policy #: 432 Latest Review Date: July 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits are payable
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationAdvanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Disclaimer This slide deck in its original and unaltered format is for educational purposes and
More informationmcrpc in 2016 How to decide the optimal treatment? N. Mottet
mcrpc in 2016 How to decide the optimal treatment? N. Mottet Disclosures Conflict of interest Chairman EAU PCa guidelines..... Therefore I'm 100% biased Castrate-resistant prostate cancer (CRPC) Definition
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationPatients Living Longer: The Promise of Newer Therapies
Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationPolicy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.
Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationDavid L. Urdal, Ph.D. Chief Scientific Officer The Development of Sipuleucel-T (Provenge ) for Active Cellular Immunotherapy for Prostate Cancer
David L. Urdal, Ph.D. Chief Scientific Officer The Development of Sipuleucel-T (Provenge ) for Active Cellular Immunotherapy for Prostate Cancer isbtc 22 nd Annual Meeting, Boston November 4, 2007 1 Forward
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationManagement Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationAfrican American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationImmunotherapy and new agents in CRPC. Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Immunotherapy and new agents in CRPC Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas, Astrazeneca, Bayer, Clovis,
More information- La Terapia Farmacologica -
XXV Congresso Nazionale AIRO Simposio AIRO-AIMN: Trattamento delle Metastasi Ossee nel Paziente con Tumore della Prostata "Ormonorefrattario": - La Terapia Farmacologica - Sergio Bracarda, Medical Oncology
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationImmunotherapy of Prostate Cancer
Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationPROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer
PROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer James L. Gulley M.D., Ph.D., F.A.C.P. Director, Clinical Trials
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationThe Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More informationManagement of castrate resistant disease; after first line hormone therapy fails
Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge
More informationDavid L. Urdal, Ph.D. Chief Scientific Officer Sipuleucel-T for the Active Cellular Immunotherapy of Prostate Cancer
David L. Urdal, Ph.D. Chief Scientific Officer Sipuleucel-T for the Active Cellular Immunotherapy of Prostate Cancer Hot Topic Symposium; isbtc Annual Meeting October 31, 2009 1 Presenter Disclosure Information
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationFocus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi?
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Terapia ormonale: quando e a chi? Paolo Andrea Zucali Dipartimento di Oncologia HUMANITAS CANCER CENTER Rozzano - Milano AGENDA Literature
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationImmunotherapy Therapy for Prostate Cancer
2006 Prostate Health Education Network African American Prostate Cancer Disparity Summit Immunotherapy Therapy for Prostate Cancer Glen W. McWilliams, MD Chief of Urology James J. Peters VAMC Assistant
More informationThe Current Prostate Cancer Landscape
A Phase 1-2 Dose-Escalation and Safety Study of ADXS-PSA Alone and of ADXS-PSA in Combination with KEYTRUDA (MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationPrognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy
DOI:10.1093/jnci/djt280 Advance Access publication October 17, 2013 The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationFrancesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
Focus sulla malattia metastatica ormonosensibile (mhspc) ADT e Chemioterapia: quando e a chi? Francesco Massari Oncologia Medica Azienda Ospedaliero Universitaria di Bologna Policlinico S. Orsola-Malpighi
More informationThe Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist
The Role of the Medical Oncologist in the Treatment of Prostate Cancer Alireza saadat hematologist and oncologist When should you see an oncologist? High risk localized disease Rising PSA after local therapy
More informationSUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments
SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival
More informationOligometastasis. Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie?
Körperstereotaxie bei oligo-metastasiertem Prostatakarzinom wann und wie in Kombination mit Systemtherapie? Daniel M. Aebersold 09. Dezember 2016 Oligometastasis JCO, 1995 1 Oligometastasis: Chance for
More informationSEQUENCING IN METASTATIC PROSTATE CANCER TREATMENT
SEQUENCING IN METASTATIC PROSTATE CANCER TREATMENT Eleni Maragkouli, Medical Oncologist Oncology Department The University of Thessaly, Medical School University Hospital of Larissa, Greece Tumour volume
More informationNon metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Non metastatic castrate-resistant prostate cancer (M0 CRPC) Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium for: Amgen, Astellas,
More information*For reprints and all correspondence: Nobuaki Matsubara, Kashiwanoha, Kashiwa, Chiba , Japan.
Japanese Journal of Clinical Oncology, 2015, 45(8) 774 779 doi: 10.1093/jjco/hyv070 Advance Access Publication Date: 15 May 2015 Original Article Original Article A multicenter retrospective analysis of
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationMitchell H. Gold, M.D. President and CEO. 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006
Mitchell H. Gold, M.D. President and CEO 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006 1 Dendreon Corporation: A Biotechnology Company on the Verge of Changing the Way
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationCME Baseline Curriculum Report
CME Baseline Curriculum Report October 14, 2010 For CME Activity: Managing Advanced Prostate Cancer in the Community Setting: A Case-based Curriculum Supported by an independent educational grant from
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationINTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER
INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER Daniel George, MD Professor of Medicine and Surgery Director of Genitourinary Oncology Program Duke Cancer Institute 1 Disclosures Consultant:
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationTreatment sequencing in metastatic castrate resistant prostate cancer
(2014) 16, 426 431 2014 AJA, SIMM & SJTU. All rights reserved 1008 682X www.asiaandro.com; www.ajandrology.com Prostate Cancer Open Access REVIEW Treatment sequencing in metastatic castrate resistant prostate
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationConvegno Nazionale AIOM Giovani 2016: News in Oncology. Daniele Alesini. Istituto Nazionale dei Tumori Regina Elena
Convegno Nazionale AIOM Giovani 2016: News in Oncology Daniele Alesini Istituto Nazionale dei Tumori Regina Elena Something Old Something New Something Borrowed Something Blue DOCETAXEL: BACK AND FORTH
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationsipuleucel-t (Provenge )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More information